OliX, a RNAi therapeutics developer, gets approval for KOSDAQ listing

SUWON, South Korea, July 23, 2018 /PRNewswire/ -- OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, has successfully completed its public listing on the Korea Securities Dealer Automated Quotation (KOSDAQ) in the Korean stock market onJuly 18. On its first d...

2018-07-23 14:42 438